| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 43598-0511-63 | 43598-0511 | Lenalidomide | Lenalidomide | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | In Use | |
| 58468-0357-03 | 58468-0357 | Alemtuzumab | Campath | 30.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD52 | Intravenous | Nov 30, 2009 | In Use | |
| 31722-0260-21 | 31722-0260 | LENALIDOMIDE | LENALIDOMIDE | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | May 11, 2023 | In Use | |
| 31722-0259-28 | 31722-0259 | LENALIDOMIDE | LENALIDOMIDE | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | May 11, 2023 | In Use | |
| 63304-0043-01 | 63304-0043 | Lenalidomide | Lenalidomide | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 4, 2023 | In Use | |
| 70771-1680-01 | 70771-1680 | LENALIDOMIDE | LENALIDOMIDE | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 7, 2023 | In Use | |
| 31722-0258-28 | 31722-0258 | LENALIDOMIDE | LENALIDOMIDE | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | May 11, 2023 | In Use | |
| 55513-0730-01 | 55513-0730 | Denosumab | XGEVA | 120.0 mg/1.7mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Nov 18, 2010 | In Use | |
| 57894-0522-01 | 57894-0522 | AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT) | Rybrevant Faspro | 3520.0 mg/22mL, 44000.0 mg/22mL | Immunotherapy | Bispecific Antibody | EGFR, MET | Subcutaneous | Feb 13, 2026 | In Use | |
| 51991-0343-01 | 51991-0343 | Pomalidomide | Pomalidomide | 2.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 28, 2026 | In Use | |
| 51991-0342-01 | 51991-0342 | Pomalidomide | Pomalidomide | 1.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 28, 2026 | In Use | |
| 00378-1937-28 | 00378-1937 | Lenalidomide | Lenalidomide | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | In Use | |
| 00378-1935-28 | 00378-1935 | Lenalidomide | Lenalidomide | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 7, 2023 | In Use | |
| 00078-0669-84 | 00078-0669 | Ofatumumab | Arzerra | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Feb 1, 2016 | Feb 1, 2016 | In Use |
| 00173-0808-05 | 00173-0808 | Ofatumumab | Arzerra | Immunotherapy | Monoclonal Antibody | CD20 | Oct 26, 2009 | Mar 31, 2012 | No Longer Used | ||
| 00085-1287-03 | 00085-1287 | Peginterferon alfa-2b | Sylatron | Immunotherapy | Cytokine | Interferon | Mar 29, 2011 | Jan 13, 2016 | No Longer Used | ||
| 00078-0669-61 | 00078-0669 | Ofatumumab | Arzerra | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Feb 1, 2016 | In Use | |
| 83257-0030-11 | 83257-0030 | Denosumab-kyqq | AUKELSO | 120.0 mg/1.7mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jan 5, 2026 | In Use | |
| 00078-0669-13 | 00078-0669 | Ofatumumab | Arzerra | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Feb 1, 2016 | Jan 31, 2026 | In Use |
| 00003-2327-11 | 00003-2327 | Ipilimumab | Yervoy | 5.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | CTLA-4 | Intravenous | Mar 25, 2011 | In Use | |
| 73380-4700-01 | 73380-4700 | MOXETUMOMAB PASUDOTOX | LUMOXITI | 1.0 mg/mL | Immunotherapy | Drug Antibody Conjugate | CD22 | Intravenous | May 15, 2020 | In Use | |
| 60505-4535-02 | 60505-4535 | Lenalidomide | Lenalidomide | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | In Use | |
| 00004-0357-99 | 00004-0357 | Peginterferon alfa-2a | Pegasys | 180.0 ug/.5mL | Immunotherapy | Cytokine | Interferon | Subcutaneous | Aug 22, 2011 | Sep 19, 2014 | No Longer Used |
| 99207-0260-01 | 99207-0260 | Imiquimod | Aldara | 50.0 mg/g | Immunotherapy | Immunomodulator | Dermatological Agent | Topical | Feb 27, 1997 | Dec 31, 2015 | No Longer Used |
| 60505-4533-02 | 60505-4533 | Lenalidomide | Lenalidomide | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | In Use |
Found 12250 results — Export these results
Home